What is Amgen?
Founded in 1980 as Applied Molecular Genetics, Amgen has evolved from a pioneering startup into a multinational powerhouse. The company specializes in the discovery, development, and manufacturing of human therapeutics, maintaining a dominant market position through its focus on complex biologics. As a leader in the biotechnology industry, Amgen utilizes its deep expertise in molecular biology to address serious illnesses, consistently setting the standard for scientific innovation and commercial execution within the life sciences sector.
How much funding has Amgen raised?
Amgen has raised a total of $2B across 2 funding rounds:
Debt
$19M
Debt
$2B
Debt (1980): $19M, investors not publicly disclosed
Debt (2022): $2B led by Citi
Key Investors in Amgen
Citi
Citigroup Inc. is a global financial services leader providing comprehensive investment banking and corporate financing solutions to multinational corporations.
Undisclosed Investors
Undisclosed Investors
What's next for Amgen?
With the successful acquisition of this recent capital, Amgen is well-positioned to accelerate its strategic initiatives, particularly in the realm of next-generation therapeutic modalities. The company's forward-looking roadmap likely involves scaling its manufacturing capabilities and expanding its clinical trial portfolio to address unmet medical needs. By maintaining a robust financial foundation, Amgen is prepared to navigate the complexities of global regulatory environments while continuing to deliver value to shareholders through sustained innovation and operational excellence in the biotechnology market.
See full Amgen company page
